Abstract
Background: The prevalence of hypogonadism is particularly high in men with obesity and T2DM. Methods: Of 361 men with hypogonadism and T2DM, 293 (81.2%) were obese, 61 (16.9%) overweight and 7 (1.9%) had normal weight. 183 received TU 1000 mg/12 weeks (T-group) following an initial 6-week interval, 178 opted against treatment (CTRL). Changes over time between groups were compared and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between groups. Results: Mean baseline age: 61.8±5.3 years, mean (median) follow-up: 8.7±3.1 (10) years. T-group: weight decreased by 22.5±0.5 kg (unadjusted numbers in brackets) (from 114.1±14.0 to 89.5±7.9) at 12 years. CTRL: weight increased by 8.5±0.5 (from 102.8±14.0 to 103.9±10.1) (p<0.0001 for both). T-group: waist circumference decreased by 13.6±0.4 cm (from 117.1±14.4 to 98.9±4.9). CTRL: WC increased by 8.5±0.4 cm (from 116.9±14.0 to 118.2±8.5) (p<0.0001 for both). T-group: BMI decreased by 7.4±0.2 kg/m² (from 36.5±4.5 to 28.9±2.6). CTRL: BMI increased by 2.8±0.2 kg/m² (from 33.4±5.3 to 33.2±3.6) (p<0.0001 for both). There was a weight loss of 19.7±0.4% in the T-group and weight gain of 9.1±0.4% in CTRL (p<0.0001 for both). Waist:height ratio decreased by 0.08±0.00 (from 0.66±0.08 to 0.56±0.03) in the T-group and increased by 0.05±0.00 (from 0.66±0.08 to 0.67±0.05) in CTRL (p<0.0001 for both). Visceral adiposity index (VAI) decreased by 3.1±0.2 (from 5.8±3.1 to 1.9±0.5) in the T-group and increased by 3.7±0.2 (from 5.1±2.5 to 8.1±3.7) in CTRL (p<0.0001 for both). Since injections were administered in the office and documented, there was a 100% adherence to testosterone therapy. Conclusions: Treatment with testosterone undecanoate injections results in profound weight loss that is maintained long-term with continued testosterone therapy. Disclosure A. Haider: Other Relationship; Self; Bayer AG. K. S. Haider: Other Relationship; Self; Bayer AG. F. Saad: Consultant; Self; Bayer AG, Stock/Shareholder; Self; AbbVie Inc., Bayer AG, Novo Nordisk. Funding Bayer AG
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
